1. 3061 Assessment of Brigatinib (AP26113) CNS Activity in Patients (Pts) With ALK+ NSCLC and intracranial metastases in a Phase 1/2 Study. (September 2015) Authors: Camidge, D.R.; Bazhenova, L.A.; Salgia, R.; Langer, C.J.; Gold, K.; Rosell, R.; Shaw, A.T.; Weiss, G.J.; Dorer, D.J.; Rivera, V.M.; Conlan, M.G.; Kerstein, D.; Gettinger, S.N. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S616 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 56 Efficacy and safety of brigatinib (AP26113) in ALK+ NSCLC: phase 1/2 trial results. (January 2016) Authors: Gettinger, S.N.; Bazhenova, L.A.; Salgia, R.; Langer, C.J.; Gold, K.; Rosell, R.; Shaw, A.T.; Weiss, G.J.; Dorer, D.J.; Rivera, V.M.; Kerstein, D.; Camidge, D.R. Journal: Lung cancer Issue: Volume 91(2016)Supplement 1 Page Start: S20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial. (January 2019) Authors: Kim, D.; Huber, R.; Ahn, M.; Langer, C.; Tiseo, M.; West, H.; Groen, H.; Reckamp, K.; Hochmair, M.; Leighl, N.; Hansen, K.H.; Gettinger, S.; Paz-Ares Rodriguez, L.; Kim, E.; Smit, E.; Kim, S.; Reichmann, W.; Kerstein, D.; Camidge, D.R. Journal: Lung cancer Issue: Volume 127(2019)Supplement 1 Page Start: S30 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗